Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Gefapixant

From Wikipedia, the free encyclopedia
Chemical compound

Pharmaceutical compound
Gefapixant
Clinical data
Trade namesLyfnua
Other namesMK-7264
ATC code
Legal status
Legal status
Identifiers
  • 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide
CAS Number
PubChemCID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.258.106Edit this at Wikidata
Chemical and physical data
FormulaC14H19N5O4S
Molar mass353.40 g·mol−1
3D model (JSmol)
  • CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC
  • InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)
  • Key:HLWURFKMDLAKOD-UHFFFAOYSA-N

Gefapixant, sold under the brand nameLyfnua, is a medication used to treatchronic (long-term) cough.[1] It acts as anantagonist of theP2RX3receptor.[2][3][4]

It was authorized for medical use in the European Union in September 2023.[1]

Medical uses

[edit]

Gefapixant isindicated for the treatment of refractory or unexplained chronic cough.[1]

Society and culture

[edit]

Names

[edit]

It was named in honour ofGeoff Burnstock.[5]

References

[edit]
  1. ^abcd"Lyfnua EPAR".European Medicines Agency. 29 September 2023. Retrieved5 October 2023.
  2. ^Muccino D, Green S (June 2019)."Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough".Pulmonary Pharmacology & Therapeutics.56:75–78.doi:10.1016/j.pupt.2019.03.006.PMID 30880151.S2CID 81982653.
  3. ^Richards D, Gever JR, Ford AP, Fountain SJ (July 2019)."Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation".British Journal of Pharmacology.176 (13):2279–2291.doi:10.1111/bph.14677.PMC 6555852.PMID 30927255.
  4. ^Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, et al. (December 2019). "Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications".Expert Opinion on Therapeutic Patents.29 (12):943–963.doi:10.1080/13543776.2019.1693542.hdl:11581/435751.PMID 31726893.S2CID 208037373.
  5. ^Ford AP, Dillon MP, Kitt MM, Gever JR (November 2021). "The discovery and development of gefapixant".Autonomic Neuroscience.235 102859.doi:10.1016/j.autneu.2021.102859.PMID 34403981.S2CID 236524967.
Expectorants
Mucolytics
Cough suppressants
Opium alkaloids,
opioids,
and derivatives
Other
Portal:


Stub icon

Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Gefapixant&oldid=1314178617"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp